TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.
1 . A topical pharmaceutical composition for treating psoriasis the composition comprising:
(a) a corticosteroid or a pharmaceutically acceptable salt or ester thereof, at a positive concentration of less than 0.05 percent by weight of the composition;
(b) a retinoid or a pharmaceutically acceptable salt or ester thereof at a positive concentration of less than 0.09 percent by weight of the composition; and
(c) a dermatologically acceptable carrier; wherein the corticosteroid is selected from the group consisting of halobetasol, clobetasol, betamethasone, diflorasone, and fluocinonide.
2 . The topical pharmaceutical composition of claim 1 , wherein the corticosteroid or a pharmaceutically acceptable salt or ester thereof is selected from the group consisting of halobetasol propionate, clobetasol propionate, betamethasone dipropionate, diflorasone diacetate, and fluocinonide.
3 . The topical pharmaceutical composition of claim 1 , wherein the retinoid is selected from the group consisting of tazarotene, bexarotene, and adapalene.
4 . The topical pharmaceutical composition of claim 1 , wherein the corticosteroid is halobetasol propionate, and the retinoid is tazarotene.
5 . The topical pharmaceutical composition of claim 1 , wherein (a) the corticosteroid is halobetasol or a pharmaceutically acceptable salt or ester thereof, and (b) the retinoid is tazarotene or a pharmaceutically acceptable tazarotenic acid salt, wherein (a) halobetasol or a pharmaceutically acceptable salt or ester thereof is present in the composition at a concentration in the range from about 0.005 to about 0.03 percent by weight of the composition, and (b) tazarotene or a pharmaceutically acceptable tazarotenic acid salt is present in the composition at a concentration in the range from about 0.005 to about 0.049 percent by weight of the composition.
6 . The topical pharmaceutical composition of claim 1 , comprising:
(a) halobetasol propionate at a concentration of 0.01 percent by weight of the composition; and
(b) tazarotene at a concentration of 0.045 percent by weight of the composition.
7 . The topical pharmaceutical composition of claim 1 , wherein the composition is an oil-in-water emulsion.
8 . The topical pharmaceutical composition of claim 7 , wherein the corticosteroid and the retinoid are dissolved in a liquid oil component of the emulsion.
9 . The topical pharmaceutical composition of claim 7 , wherein the liquid oil component comprises a DCAE, MCAE, or combinations thereof.
10 . (canceled)
11 . The topical pharmaceutical composition of claim 7 , wherein an oil phase of the oil-in-water emulsion comprises a liquid oil component, which comprises diethyl sebacate and light mineral oil.
12 . The topical pharmaceutical composition of claim 11 , wherein the corticosteroid and the retinoid are dissolved in the liquid oil component of the emulsion.
13 . The topical pharmaceutical composition of claim 7 , wherein the emulsion is a lotion.
14 . (canceled)
15 . A method of treating psoriasis, the method comprising topically applying a pharmaceutical composition to an affected area of a body of a subject suffering from psoriasis; wherein the composition comprises:
(a) a corticosteroid or a pharmaceutically acceptable salt or ester thereof, at a positive concentration of less than 0.05 percent by weight of the composition;
(b) a retinoid or a pharmaceutically acceptable salt or ester thereof at a positive concentration of less than 0.09 percent by weight of the composition; and
(c) a dermatologically acceptable carrier; wherein the corticosteroid is selected from the group consisting of halobetasol, clobetasol, betamethasone, diflorasone, and fluocinonide; and wherein said applying is carried out one or more times per day for a period of time sufficient to treat such psoriasis.
16 . The method of claim 15 , wherein said applying is carried out once per day for eight weeks.
17 . – 19 . (canceled)
20 . The method of claim 15 , wherein (a) the corticosteroid is halobetasol or a pharmaceutically acceptable salt or ester thereof; and (b) the retinoid is tazarotene or a pharmaceutically acceptable tazarotenic acid salt; wherein (a) halobetasol or a pharmaceutically acceptable salt or ester thereof is present in the composition at a concentration in the range from about 0.005 to about 0.03 percent by weight of the composition; and (b) tazarotene or a pharmaceutically acceptable tazarotenic acid salt is present in the composition at a concentration in the range from about 0.005 to about 0.049 percent by weight of the composition.
21 . The method of claim 15 comprising: (a) halobetasol propionate at a concentration of 0.01 percent by weight of the composition, and (b) tazarotene at a concentration of 0.045 percent by weight of the composition.
22 . The method of claim 15 , wherein the composition is an oil-in-water emulsion.
23 . The method of claim 22 , wherein the corticosteroid and the retinoid are dissolved in a liquid oil component of the emulsion.
24 . The method of claim 22 , wherein the liquid oil component comprises a DCAE, MCAE, or combinations thereof.
25 . – 27 . (canceled)
28 . The method of claim 22 , wherein the emulsion is a lotion.
29 . – 30 . (canceled)